The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

H.C. Wainwright analyst Vernon Bernardino reiterated a Hold rating on Cassava Sciences (SAVA – Research Report) today. The company’s shares ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company's announcement of securing an exclusive license to a method of treatment patent f ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...